abcam

ab204954

Anti-Ezrin antibody [6F1C3]

Key facts

Isotype	IgG1
Host species	Mouse
Storage buffer	Preservative: 0.05% Sodium azide Constituents: PBS
Form	Liquid
Clonality	Monoclonal
Immunogen	Recombinant Fragment Protein within Human EZR aa 250-500. The exact immunogen used to generate this antibody is proprietary information. Database link P15311
Clone number	6F1C3
Purification technique	Affinity purification Protein G
Concentration	1 mg/mL The concentration of this product may be batch-dependent Batch concentration finder →
Purification notes	Purified from tissue culture supernatant.

Reactivity data

Flow Cyt

Tested

Species	Human
Dilution info	1/200 - 1/400
Notes	-

Predicted

Species	Mouse, Rat, Rabbit, Cow
Dilution info	-
Notes	-

WB

Tested

Species	Human
Dilution info	1/500 - 1/2000
Notes	-

Predicted

Species	Mouse, Rat, Rabbit, Cow
Dilution info	-
Notes	-

ICC/IF

Tested

Species	Human
Dilution info	1/200 - 1/1000
Notes	-

Predicted

Species	Mouse, Rat, Rabbit, Cow
Dilution info	-
Notes	-

Target data

See full target information EZR

Function	Probably involved in connections of major cytoskeletal structures to the plasma membrane. In epithelial cells, required for the formation of microvilli and membrane ruffles on the apical pole. Along with PLEKHG6, required for normal macropinocytosis.

Storage

Shipped at conditions	Blue Ice
Appropriate short-term storage duration	1-2 weeks
Appropriate short-term storage conditions	+4°C
Appropriate long-term storage conditions	-20°C
Aliquoting information	Upon delivery aliquot
Storage information	Avoid freeze / thaw cycle

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary	Ezrin also known as cytovillin or villin-2 is a protein belonging to the ezrin-radixin-moesin (ERM) family. It is approximately 81 kDa in molecular weight. Ezrin plays a critical role in linking the actin cytoskeleton to the plasma membrane. This interaction occurs through its ability to bind to membrane proteins and phospholipids facilitating structural support and signal transduction. Ezrin is widely expressed in epithelial tissues but it also occurs in other cell types such as lymphocytes and osteoclasts.
Biological function summary	Ezrin functions as a membrane-microfilament linker and is essential for maintaining cell shape adhesion and motility. It is an integral component of many cellular structures including microvilli and ruffles. Ezrin's activity often involves forming complexes with other proteins such as EBP50 and F-actin which are fundamental for its role in cellular morphogenesis. These interactions allow ezrin to regulate membrane surface structure and cell surface organization.
Pathways	Ezrin participates in various signaling pathways that are essential for cell migration and invasion. One key pathway is the Rho family of GTPases which regulates actin cytoskeleton dynamics. Ezrin interacts with proteins like Rho-associated kinase (ROCK) that influence cell contraction and motility. Additionally ezrin is involved in the MAPK/ERK pathway which influences cell growth and survival by interacting with other signaling molecules.

Associated diseases and disorders	Ezrin shows significant relevance to cancer progression and metastasis particularly in conditions like osteosarcoma. Ezrin overexpression correlates with increased metastatic potential and poor clinical outcomes. It also has implications in allergic diseases due to its role in immune cell function. In these contexts ezrin interacts with SRC family kinases which are important for transmitting signals from cell-surface receptors to downstream pathways influencing disease development and progression.

Product promise

Tested

We have tested this species and application combination and it works. It is covered by our product promise.

Expected

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

Predicted

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

Not recommended


We do not recommend this combination. It is not covered by our product promise.

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.


5 product images



Flow Cytometry - Anti-Ezrin antibody [6F1C3] (ab204954)

Ezrin Flow Cytometry staining using mouse Anti-Ezrin antibody


Flow cytometric analysis of A431 cells labeling Ezrin with ab204954 at 1/200 (green) or negative control (red)



Immunocytochemistry/ Immunofluorescence - Anti-Ezrin antibody [6F1C3] (ab204954)

Ezrin Immunocytochemistry/ Immunofluorescence staining using mouse Anti-Ezrin antibody

Immunofluorescent analysis of Hela cells labeling Ezrin with ab204954 at 1/200 (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin.



Western blot - Anti-Ezrin antibody [6F1C3] (ab204954)

All lanes:
Western blot - Anti-Ezrin antibody [6F1C3] (ab204954) at 1/500 dilution


Lane 1:
Jurkat cell lysate

Lane 2:
A431 cell lysate

Lane 3:
MCF-7 cell lysate

Lane 4:
HeLa cell lysate

Predicted band size: 69 kDa




Western blot - Anti-Ezrin antibody [6F1C3] (ab204954)

(Expected MW is 47.1 kDa)
All lanes:
Western blot - Anti-Ezrin antibody [6F1C3] (ab204954) at 1/500 dilution

All lanes:
Human Ezrin (aa: 292-464) recombinant protein.

Predicted band size: 69 kDa



Western blot - Anti-Ezrin antibody [6F1C3] (ab204954)

All lanes:
Western blot - Anti-Ezrin antibody [6F1C3] (ab204954) at 1/500 dilution

Lane 1:
HEK293 cell lysate

Lane 2:
Ezrin (AA: 292-464)-hIgGFc transfected HEK293 cell lysate

Predicted band size: 69 kDa

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.